



Life Settlement Assets PLC – Ordinary Share A

Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Estimated Performance



Commentary

Investment TermsConning's 15th annual life settlement review takes a preliminary look at the
potential impacts COVID-19 could have on life settlements. Some of these
impacts could represent longer-term challenges and opportunities for life
settlement investors. There are several drivers that favour continued growth
in the life settlement market. Investors will have a larger number of policies
to select from because of the increasing number of retiring baby boomers. In
addition, the economic disruption from COVID-19 may increase the appeal of
life settlements to those retirees. The risk for investors, however, is the
potential impact on cost of insurance charges due to increased pressure on
insurers from extremely low interest rates.

NAV/Share 2.0900


The Share Class is reporting a performance of -1.17% for the month of September. Ten small face HIV maturities were registered, contributing a total Death Benefit of \$0.3M; no maturities were registered in the non-HIV segment this month. In addition, a small portfolio of fractionals, to which the trust was overwhelmingly already exposed to, was added in order to prevent any undue lapsing.

Number Of Policies	Death Benefits (USD)	Matured Policies YTD		Maturities YTD (USD)
4 480	460 986 263	96		15 255 541
Trust Investment Manager	Acheron Capital Ltd.	Company ISCA Administration Services Limite Secretary		inistration Services Limited
Administrator	Compagnie Européenne de Révision	ISIN Ticker	GB00BF1Q4B05 LSAA	
Auditor	Info	life@ache +44 207 2	eroncapital.com 58 5990	


September 2020









Distribution By Gender




Distribution by Insurance Company



Distribution by Issue Date⁽²⁾ (Yrs)




Maturities Since Inception



(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.
(2)Distribution by issue dates reflects the time since the life insurance policy was issued.
Source of Data: Acheron Capital Ltd unless otherwise stated.








Maturities September 2020

Number of policies matured in September 2020	10
Corresponding number of insured	3
Total death benefit in September 2020(US\$)	260 199
Valuation of Matured policies in Book (US\$)	19 240



Top 10 Coverage

Premiums Situation (US\$)⁽¹⁾

Servicers Premiums Projection for the next 12 months	\$ 13.3M	
Mortality Adjusted Premiums Projection for the next 12 months	\$ 12.6M	
Estimated COI Net of Mortality for the next 12 months	\$ 11.6M	

Cash Situation (US\$)⁽¹⁾

		Total Face	Age		Cash at hand and similar	\$ 11.9M
Insured	Face (millions)	(millions)	(ALB)	Expiration Age*		
1	3.0/1.8/1.4/0.5	6.7	96	103/100/115/103	Gross Cash in Policies ⁽²⁾	\$ 49.1M
2	4.4/1.2	5.6	95	100/120	(estimated as of end 2019)	
3	1.8/1.7/1.5	5.0	77	121/100/100	Loan on Cash in Policies	\$ 14.0M
4	4.0/0.5	4.5	97	100/100	(estimated as of end 2019)	·
5	4.1	4.1	95	100	Net Cash in Policies ⁽²⁾	\$ 35.1M
6	1.6/0.9/0.6/0.4/0.3/0.1	3.9	92	100/100/100/95/100/115	(estimated as of end 2019)	φ 33.1 Μ
7	3.4	3.4	79	100	Maturities to be received	\$ 6.7M
8	3.0	3.0	93	100		φ στη τη
9	2.7	2.7	100	120		
10	2.4	2.4	98	100/100		

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Cash for ABC policies not included. Surrender charge included.

*In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.